Clinical Trial Update: Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel plus gemcitabine with or without tocilizumab in unresectable pancreatic carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Herlev Hospital | Conditions: Unresectable Pancreatic Carcinoma | Phase 2 | Status: COMPLETED